Tivozanib information

Tivozanib
Clinical data
Trade names	Fotivda
Other names	AV-951
AHFS/Drugs.com	Monograph
MedlinePlus	a621018
License data	EU EMA: by INN; US DailyMed: Tivozanib;
Routes of; administration	By mouth
ATC code	L01EK03 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Protein binding	>99%
Elimination half-life	4.5–5.1 days
Excretion	79% feces, 12% urine
Identifiers
CAS Number	475108-18-0;
PubChem CID	9911830;
IUPHAR/BPS	6058;
ChemSpider	8087481;
UNII	172030934T;
KEGG	D09683;
ChEMBL	ChEMBL1289494;
CompTox Dashboard (EPA)	DTXSID20963865 ;
Chemical and physical data
Formula	C22H19ClN4O5
Molar mass	454.87 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(Nc1noc(c1)C)Nc4ccc(Oc2c3cc(OC)c(OC)cc3ncc2)cc4Cl;
	InChI InChI=InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28); Key:SPMVMDHWKHCIDT-UHFFFAOYSA-N;

Tivozanib, sold under the brand name Fotivda, is a medication used for the treatment of advanced renal cell carcinoma (kidney cancer).^[3] It is an oral VEGF receptor tyrosine kinase inhibitor.^[3]

The most common side effects include fatigue (tiredness), hypertension (high blood pressure), diarrhea, decreased appetite, nausea, dysphonia (voice changes), hypothyroidism, cough, and stomatitis.^[4]^[3]^[5]

Tivozanib was approved for medical use in the European Union in August 2017,^[4] and in the United States in March 2021.^[3]^[5]

^ "Fotivda 890mcg hard capsules Summary of Product Characteristics (SmPC)". (emc). 4 April 2023. Archived from the original on 6 April 2023. Retrieved 23 July 2023.
^ "Fotivda- tivozanib capsule". DailyMed. Archived from the original on 13 September 2021. Retrieved 12 September 2021.
^ ^a ^b ^c ^d ^e "FDA approves tivozanib for relapsed or refractory advanced renal cell". U.S. Food and Drug Administration. 10 March 2021. Archived from the original on 11 March 2021. Retrieved 16 March 2021. This article incorporates text from this source, which is in the public domain.
^ ^a ^b ^c "Fotivda EPAR". European Medicines Agency (EMA). Archived from the original on 13 May 2021. Retrieved 16 March 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ ^a ^b Cite error: The named reference Fotivda FDA snapshot was invoked but never defined (see the help page).

[1] "Fotivda 890mcg hard capsules Summary of Product Characteristics (SmPC)". (emc). 4 April 2023. Archived from the original on 6 April 2023. Retrieved 23 July 2023.

[Fotivda_FDA_label-2] "Fotivda- tivozanib capsule". DailyMed. Archived from the original on 13 September 2021. Retrieved 12 September 2021.

[FDA_tivozanib-3] "FDA approves tivozanib for relapsed or refractory advanced renal cell". U.S. Food and Drug Administration. 10 March 2021. Archived from the original on 11 March 2021. Retrieved 16 March 2021. This article incorporates text from this source, which is in the public domain.

[Fotivda_EPAR-4] "Fotivda EPAR". European Medicines Agency (EMA). Archived from the original on 13 May 2021. Retrieved 16 March 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[Fotivda_FDA_snapshot-5] Cite error: The named reference Fotivda FDA snapshot was invoked but never defined (see the help page).

Tivozanib information

and 24 Related for: Tivozanib information

Tivozanib

Dexamethasone

Erythropoietin

Insulin

Testosterone

Amitriptyline

Fruquintinib

Elranatamab

Nerve growth factor

Neurotrophic factors

Dehydroepiandrosterone

Cetuximab

Osimertinib

Bevacizumab

Cabozantinib

Trastuzumab deruxtecan

HER2

Vemurafenib

Epidermal growth factor receptor

Cerebrolysin

Tyrosine kinase inhibitor

Trastuzumab emtansine

Imatinib

Wnt signaling pathway